# Simcha Therapeutics Holding Company

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/simcha-therapeutics-holding-company

- Industry: Biotechnology
- Headquarters: New Haven, US
- Website: www.simchatx.com
- Total disclosed funding: $65M
- Latest round: Series B (Jan 27, 2022)
- Investors on record: 9

## About

Based in Connecticut, US, and founded in 2018, Simcha Therapeutics Holding Company, LLC operates as a clinical stage immunobiology company specializing in the development of cytokine therapeutics for patients. In January 2022, Simcha Therapeutics Holding Company, LLC raised USD 40 million in Series B funding led by SR One, with participation from ArrowMark Partners, BVF Partners, Logos Capital, Rock Springs Capital and Samsara BioCapital.

Simcha Therapeutics Holding Company, LLC develops ST-067, which is an IL-18 cytokine that has shown potent antitumor effects in animal models, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors. The company focuses on cytokines immunotherapies to fight cancer diseases by stimulating the immune system.

## Funding rounds

- Series B, Jan 27, 2022, $40M — SR One, ArrowMark Partners, BVF Partners, Rock Springs Capital, Samsara BioCapital, Logos Capital
- Series A, Jun 24, 2020, $25M — Hong Shan, Connecticut Innovations, Wuxi AppTec Group

## Investors

- Hong Shan — Series A
- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series A
- Wuxi AppTec Group — Series A
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B
- ArrowMark Partners — Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- Rock Springs Capital — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B